---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002765"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:18:46.664838+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences Q1 net income $25M; Phase 3 Alzheimer's trials on track with >1,900 patients

## Summary
- Net income of $25.0M vs net loss $24.3M in Q1 2023; non-cash warrant gain drove the swing.
- $126.3M in gross proceeds from warrant exercise; cash & equivalents $124.2M, no debt as of March 31.
- Over 1,900 patients randomized across two Phase 3 simufilam trials; >735 patients have completed.
- Top-line data for 52-week RETHINK-ALZ expected year-end 2024; 76-week REFOCUS-ALZ data mid-2025.
- Q1 R&D spend $16.2M, down from $22.1M YoY; H1 2024 operating cash burn guided at $35-45M.

## SEC filing metadata
- accession: 0001171843-24-002765
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184324002765/0001171843-24-002765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184324002765/f8k_051024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002765
- JSON: https://secwatch.observer/filing/0001171843-24-002765.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002765.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.